Overview

A Study of the HSP90 Inhibitor AUY922

Status:
Terminated

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if AUY922 can help to control refractory or recurrent lymphoma. The safety of AUY922 will also be studied. AUY922 is designed to block tumor growth by blocking a protein.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Novartis